Lipid nanoparticles of zaleplon for improved oral delivery by Box–Behnken design: optimization, in vitro and in vivo evaluation

References

• Andrew JH, William NC. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deli Rev 1997;25:103–28.
   Web of Science ®Google Scholar
• Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413–20.
   PubMed Web of Science ®Google Scholar
• Charman WN, Porter CJH. Lipophilic prodrugs designed for intestinal lymphatic transport. Adv Drug Deli Rev 1996;19:149–69.
   Web of Science ®Google Scholar
• Mühlen AZ, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled release drug delivery – drug release and release mechanism. Eur J Pharm Biopharm 1998;45:149–55.
   PubMed Web of Science ®Google Scholar
• Schwarz C, Mehnert W, Lucks JS, Müller RH. Solid lipid nanoparticles (SLN) for controlled drug delivery-I. Production, characterization and sterilization. J Control Release 1994;30:83–96.
   Web of Science ®Google Scholar
• Müller RH, Mehnert W, Lucks JS. Solid lipid nanoparticles (SLN)-an alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm 1995;41:62–9.
   Web of Science ®Google Scholar
• Schwarz C. Solid lipid nanoparticles (SLN) for controlled drug delivery II. Drug incorporation and physicochemical characterization. J Microencapsul 1999;16:205–13.
   PubMed Web of Science ®Google Scholar
• Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm 2000;50:161–77.
   PubMed Web of Science ®Google Scholar
• Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001;47:165–96.
   PubMed Web of Science ®Google Scholar
• Mehnert W, Mäder K. Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev 2012;64:83–101.
   Web of Science ®Google Scholar
• Üner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nano 2007;2:289–300.
   Google Scholar
• Lewis GA, Mathieu D, Phan TLR. Editors. Pharmaceutical experimental design. New York: Marcel Dekker Inc; 1999.
   Google Scholar
• Box GPE, Wilson KB. On the experimental attainment of optimum conditions. J Royal Stat Soc Ser B 1951;1:1–45.
   Google Scholar
• Box GEP, Behnken DW. Some new three level designs for the study of quantitative variables. Technometrics 1960;2:455–75.
   Google Scholar
• Dooley M, Plosker G. Zaleplon: a review of its use in the treatment of insomnia. Drugs 2000;60:413–45.
   PubMed Web of Science ®Google Scholar
• Winkler A, Auer C, Doering BK, Rief W. Drug treatment of primary insomnia: a meta-analysis of polysomnographic randomized controlled trials. CNS Drugs 2014;28:799–816.
   PubMed Web of Science ®Google Scholar
• Waghmare A, Pore Y, Kuchekar B. Development and characterization of zaleplon solid dispersion systems: a technical note. AAPS PharmSciTech 2008;9:536–43.
   PubMed Web of Science ®Google Scholar
• Popescu C, Manda P, Juluri A, et al. Enhanced dissolution efficiency of zaleplon solid dispersions via modified β-cyclodextrin molecular inclusion complexes. J Pharm Pharm Sci 2015;1:1–10.
   Google Scholar
• Janga KY, Jukanti R, Velpula A, et al. Bioavailability enhancement of zaleplon via proliposomes: role of surface charge. Eur J Pharm Biopharm 2012;80:347–57.
   PubMed Web of Science ®Google Scholar
• Janga KY, Jukanti R, Velpula A, et al. In situ absorption and bioavailability studies of zaleplon loaded self- nanoemulsifying powders (SNEPs). J Microencapsulation 2013;30:167–72.
   Web of Science ®Google Scholar
• Narendar D, Arjun N, Dinesh S, Karthik J. Biopharmaceutical and preclinical studies of efficient oral delivery of zaleplon as semisolid dispersions with self-emulsifying lipid surfactants. Int J Pharm Sci Nanotech 2016;9:1–8.
   Google Scholar
• Chinna Reddy P, Narendar D, Sunil Kumar B, et al. Combined dosage form of pioglitazone and felodipine as mucoadhesive pellets via hot melt extrusion for improved buccal delivery with application of quality by design approach. J Drug Deli Sci Tech 2015;30:209–19.
   Web of Science ®Google Scholar
• Narendar D, Kishan V. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation. Drug Deliv 2016;23:395–404.
   PubMed Web of Science ®Google Scholar
• Nageswara Rao T, Srineevasula Reddy EG, Patrudu TB, Parvathamma T. Estimation of zaleplon by a new RP-HPLC method. J Chem Pharm Res 2012;4:3010–4.
   Google Scholar
• Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release 2004;95:627–38.
   PubMed Web of Science ®Google Scholar
• Narendar D, Kishan V. Pharmacokinetic and pharmacodynamic studies of nisoldipine loaded solid lipid nanoparticles developed by central composite design. Drug Dev Ind Pharm 2015;41:1968–77.
   PubMed Web of Science ®Google Scholar
• Cavalli R, Caputo O, Carlotti ME, et al. Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles. Int J Pharm 1997;148:47–54.
   Web of Science ®Google Scholar
• Zhang B, Zhang Z, Tian Y, et al. High-performance liquid chromatography–atmospheric pressure chemical ionization-mass spectrometry determination of zaleplon in human plasma. J Pharm Biomed Anal 2006;40:707–14.
   PubMed Web of Science ®Google Scholar
• Howard MD, Lu X, Jay M, Dziubla TD. Optimization of the lyophilization process for long-term stability of solid-lipid nanoparticles. Drug Dev Ind Pharm 2012;38:1270–9.
   PubMed Web of Science ®Google Scholar
• Usha Kiranmai G, Narendar D, Kishan V. Preparation, characterization and in vivo evaluation of felodipine solid lipid nanoparticles to improve the oral bioavailability. Int J Pharm Sci Nanotech 2015;8:1–8.
   Google Scholar
• Dodiya S, Chavhan S, Korde A, Sawant KK. Solid lipid nanoparticles and nanosuspension of adefovir dipivoxil for bioavailability improvement: formulation, characterization, pharmacokinetic and biodistribution studies. Drug Dev Ind Pharm 2013;39:733–43.
   PubMed Web of Science ®Google Scholar
• Choi MJ, Briancon S, Andrieu J, et al. Effect of Freeze-Drying process conditions on the stability of nanoparticles. Dry Tech 2004;22:335–46.
   Google Scholar
• Dahan A, Hoffman A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Control Release 2008;129:1–10.
   PubMed Web of Science ®Google Scholar